Table 2.
Results from the EORTC QLQ evaluated over time in different adjuvant treatment groups
| EORTC QLQ-C30 | Type of adjuvant treatment |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| no adjuvant treatment (OS) |
intravitreal injection (IN) |
endoresection/drainage (SU) |
||||||||||
| mean | ±SD | t1:t2 | t2:t3 | mean | ±SD | t1:t2 | t2:t3 | mean | ±SD | t1:t2 | t2:t3 | |
| Global health score | ||||||||||||
| t1 | 68.27 | 20.26 | p = 0.319 | 54.90 | 25.01 | p = 0.061 | 68.52 | 17.35 | p = 0.229 | |||
| t2 | 71.25 | 18.44 | p = 0.495 | 67.22 | 16.80 | p = 0.665 | 64.37 | 17.66 | p = 0.018 | |||
| t3 | 73.21 | 19.12 | 67.86 | 21.40 | 72.57 | 19.58 | ||||||
| Functional scales | ||||||||||||
| Physical functioning | ||||||||||||
| t1 | 88.05 | 18.20 | p = 0.049 | 84.71 | 22.33 | p = 0.526 | 91.67 | 10.28 | p = 0.020 | |||
| t2 | 85.39 | 21.45 | p = 0.041 | 89.17 | 18.68 | p = 0.312 | 86.89 | 13.62 | p = 0.879 | |||
| t3 | 88.81 | 17.76 | 86.67 | 26.41 | 85.56 | 19.23 | ||||||
| Role functioning | ||||||||||||
| t1 | 74.71 | 27.79 | p = 0.954 | 68.63 | 33.27 | p = 0.748 | 80.25 | 24.04 | p = 0.002 | |||
| t2 | 74.32 | 26.45 | p = 0.649 | 73.96 | 20.16 | p = 0.277 | 67.82 | 25.95 | p = 0.183 | |||
| t3 | 76.19 | 26.56 | 65.48 | 25.71 | 71.53 | 25.29 | ||||||
| Emotional functioning | ||||||||||||
| t1 | 71.05 | 22.55 | p = 0.050 | 63.73 | 25.51 | p = 0.365 | 70.99 | 24.61 | p = 0.314 | |||
| t2 | 75.91 | 22.85 | p = 0.730 | 70.56 | 24.57 | p = 0.477 | 69.35 | 18.29 | p = 0.689 | |||
| t3 | 78.17 | 21.41 | 70.63 | 25.73 | 67.59 | 22.91 | ||||||
| Cognitive functioning | ||||||||||||
| t1 | 86.84 | 19.60 | p = 0.403 | 77.45 | 29.43 | p = 0.490 | 83.95 | 17.59 | p = 0.210 | |||
| t2 | 83.06 | 20.30 | p = 0.214 | 77.78 | 22.42 | p = 0.645 | 80.00 | 22.49 | p = 0.202 | |||
| t3 | 82.14 | 20.31 | 80.95 | 15.82 | 77.78 | 17.49 | ||||||
| Social functioning | ||||||||||||
| t1 | 81.58 | 21.75 | p = 0.062 | 74.51 | 29.53 | p = 0.591 | 80.86 | 24.33 | p = 0.146 | |||
| t2 | 86.67 | 22.51 | p = 0.046 | 80.00 | 24.56 | p = 0.833 | 77.01 | 20.61 | p = 0.710 | |||
| t3 | 86.31 | 22.04 | 80.95 | 24.33 | 77.78 | 25.85 | ||||||
| Single item | ||||||||||||
| Pain | ||||||||||||
| t1 | 15.23 | 24.22 | p = 0.229 | 19.61 | 32.93 | p = 0.450 | 9.87 | 15.51 | p = 0.063 | |||
| t2 | 11.20 | 21.88 | p<0.001 | 9.38 | 22.75 | p = 0.045 | 16.11 | 18.82 | p = 0.289 | |||
| t3 | 18.97 | 25.59 | 16.96 | 24.51 | 17.86 | 24.31 | ||||||
Values are the mean scores and standard deviations (SD). t1, immediately after PT; t2,3 months after PT; t3,12 months after PT. Bold font: p value ≤0.05 indicates a significant change between the indicated assessment points, according to the paired Wilcoxon signed-rank test. QLQ, quality of life questionnaire; EORTC, European Organization for Research and Treatment of Cancer; PT, proton therapy.